Effects of Repeated Injections of the Neurotensin Analog NT69L on Dopamine Release and Uptake in Rat Striatum in Vitro
Affiliations
The effect of five daily intraperitoneal (i.p.) injections of NT69L on in vitro dopamine release, uptake, and [(3)H]NT binding in rat striatal tissue was investigated. NT69L perfusion increased K(+)-evoked and electrically evoked [(3)H]DA release. NT receptor-1 antagonist SR48692 inhibited the stimulatory effect of NT69L on K+-evoked [(3)H]DA release, but not on electrical depolarization. Pretreatment with NT69L, in vivo, daily for 5 days, did not cause significant change in K(+) evoked [(3)H]DA release, but reduced electrically evoked [(3)H]DA release induced by NT69L perfusion. Repeated perfusion with NT69L in vitro caused marked reduction on K(+)-evoked [(3)H]DA release and no change in electrically evoked [(3)H]DA release. [(3)H]NT binding was not significantly changed by one injection but was decreased after five injections of NT69L. Desensitization to the effects of NT69L in vitro was different depending upon whether tissue was preexposed to the compound in vivo or in vitro. These results provide further proof for the involvement of different NT receptor subtypes in mediating the effect of NT69L on dopamine release evoked by K(+) or electrical depolarization.
Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders.
Vadnie C, Park J, Abdel Gawad N, Ho A, Hinton D, Choi D Front Neurosci. 2014; 8:288.
PMID: 25278825 PMC: 4166902. DOI: 10.3389/fnins.2014.00288.
Smith K, Boules M, Williams K, Fauq A, Richelson E Behav Brain Res. 2011; 224(2):344-9.
PMID: 21718721 PMC: 3159772. DOI: 10.1016/j.bbr.2011.06.014.
Li Z, Boules M, Williams K, Peris J, Richelson E Brain Res. 2009; 1311:28-36.
PMID: 19948149 PMC: 2812638. DOI: 10.1016/j.brainres.2009.11.048.
Briody S, Boules M, Oliveros A, Fauq I, Richelson E Behav Brain Res. 2009; 207(1):118-24.
PMID: 19800922 PMC: 2788020. DOI: 10.1016/j.bbr.2009.09.044.
Feifel D, Melendez G, Murray R, Tran D, Rullan M, Shilling P Psychopharmacology (Berl). 2008; 200(2):197-203.
PMID: 18568338 PMC: 2755044. DOI: 10.1007/s00213-008-1197-5.